Literature DB >> 19878760

Translation of clinical studies to clinical practice: survey on the treatment of nonarteritic anterior ischemic optic neuropathy.

Edward J Atkins, Beau B Bruce, Nancy J Newman, Valérie Biousse.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19878760     DOI: 10.1016/j.ajo.2009.07.003

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  6 in total

1.  Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy?

Authors:  Andrew G Lee; Valérie Biousse
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

2.  Nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 3.  Systemic corticosteroids in nonarteritic ischemic optic neuropathy.

Authors:  Nagham Al-Zubidi; Jason Zhang; Arielle Spitze; Andrew G Lee
Journal:  Indian J Ophthalmol       Date:  2014-10       Impact factor: 1.848

4.  Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis.

Authors:  Jun Chen; Jie Zhu; Li Chen; Chen Hu; Yi Du
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Visual outcome of mega-dose intravenous corticosteroid treatment in non-arteritic anterior ischemic optic neuropathy - retrospective analysis.

Authors:  Michael Kinori; Iris Ben-Bassat; Yael Wasserzug; Angela Chetrit; Ruth Huna-Baron
Journal:  BMC Ophthalmol       Date:  2014-05-03       Impact factor: 2.209

6.  Optical Coherence Tomography Angiography Assessment of the Peripapillary Vessel Density and Structure in Patients with Nonarteritic Anterior Ischemic Optic Neuropathy: A Meta-Analysis.

Authors:  Ling Ling; Kaibao Ji; Liping Xie; Feifei Gao; Qinglin Zhang; Yiqiao Xing; Wentian Zhou
Journal:  Biomed Res Int       Date:  2020-10-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.